drugset
drugset / Trial / NCT06788912

Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)

NCT06788912 ↗

Phase 2 Active not recruiting 60 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupOpen-labelTreatment

Summary

The main goals are after treatment given before surgery, to measure the number of people who have no signs of cancer cells in tumors and lymph nodes removed during surgery; and to learn about whether the cancer gets smaller or goes away by measuring the number of people with a certain number of living cancer cells in the tumor removed during surgery.

Timeline

Start
2025-03-20
Primary completion
2032-02-06
Completion
2032-02-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule 5 unknown Intravenous
Subject Carboplatin Small molecule 6 unknown Intravenous
Subject Cisplatin Other / unclassified 75 mg/m2 Intravenous
Subject Gemcitabine Small molecule 1000 mg/m2 Intravenous
Subject Paclitaxel Small molecule 175 mg/m2 Intravenous
Subject Paclitaxel Small molecule 200 mg/m2 Intravenous
Subject Pembrolizumab Monoclonal antibody 200 mg Intravenous
Subject Pemetrexed Small molecule 500 mg/m2 Intravenous
Subject Sacituzumab Tirumotecan Other / unclassified 4 mg/kg Intravenous
Background Acetaminophen Small molecule — —
Background Dexamethasone Small molecule 2 ml Oral
Background Dexamethasone Small molecule 5 ml Oral
Background Dexamethasone Small molecule 8 mg —
Background Dexamethasone Small molecule 10 mg —

Indications

lung cancer